Life Technologies Bolsters its 60 Percent Market Share Lead in Benchtop
Sequencers with 12 New Ion Torrent™ Products
More than 90 peer-reviewed papers and the world's largest online sequencing
community reflects broad adoption of Ion Torrent™ technology
CARLSBAD, Calif., Feb. 20, 2013
CARLSBAD, Calif., Feb. 20, 2013 /PRNewswire/ -- Life Technologies Corporation
(NASDAQ: LIFE) today announced a dozen innovative new products for the Ion
Torrent™ platform that will make sequencing faster, simpler and more
accessible for scientists, driving discovery and advancing clinical research
around the world.
"These new products continue the pace of relentless innovation that in just
two years enabled Ion Torrent™ semiconductor sequencing technology to scale
more than 1,000-fold and gain a 60 percent market share of benchtop
sequencers," said Dr. Jonathan M. Rothberg, Ion TorrentFounder and CEO."More
than 90 peer-reviewed publications and the world's largest online sequencing
community, with over 15,000 members, reflect the huge demand for faster,
simpler and more affordable sequencing."
Ion Torrent™ technology continues to simplify and automate key workflows,
decreasing turnaround times and expanding access to next-generation sequencing
for both basic and translational researchers.
oIon Library Equalizer™ Kits eliminate the need for library quantification
and library dilutions prior to clonal amplification for Ion AmpliSeq™ DNA
and Ion genomic fragment libraries. The kit reduces hands-on time, sample
variability and reagent cost, while increasing processing speed for
oIon TargetSeq™ Exome Rapid Protocol reduces the capture step to just 16
hours, enabling whole human exome enrichment and sequencing on the Ion
Proton™ Sequencer in as little as a day and a half, making the Ion Exome
sequencing workflow the fastest method for performing human exome
sequencing. The protocol is now available from Ion field application
oIon AmpliSeq™ RNA Library Kit requires as little as 500 pg ofunfixed RNA
and 5 ng of FFPE RNA and is compatible with Ion Express™ Barcode Modules
for multiplexing multiple samples on a single Ion semiconductor sequencing
oIon Total RNA-Seq Kit for AB Library Builder™ System enables the analysis
of either whole transcriptome or small RNA expression with a single
reagent kit. The kit requires as little as 500 ng of total RNA,or as
little as 50 ng of enriched small RNA.
Ion AmpliSeq™ Technology
Ion AmpliSeq™ technology is the industry-leading solution for targeted
sequencing, with over 100,000 reactions run in the past year. Today, Life
Technologies is launching the first targeted RNA panels for a next-generation
sequencer, a targeted mouse DNA panel and two new community panels. All of the
products below are available at www.ampliseq.com.
oIon AmpliSeq™ Designer 2.0 now enables researchers to design panels for
sequencing human DNA and RNA, as well as mouse DNA. The Ion AmpliSeq™
Designer now supports up to 6,144 primer pairs in a single tube, up to 5
Mb designs, the industry's highest multiplexed solution.
oIon AmpliSeq™ RNA Cancer Panel is a single pool that targets the same 50
tumor suppressor and oncogenes covered by the Ion AmpliSeq™ DNA Cancer
Hotspot Panel v2.
oIon AmpliSeq™ RNA Apoptosis Panel uses a single pool of primers
representing 267 genes involved in the cellular apoptosis pathway,
including genes associated with death receptor mediated apoptosis, c-myc
and p53 mediated apoptosis.
oIon AmpliSeq™ RNA Custom Panels enable scientists to choose from over
20,000 targeted genes to survey gene expression fold changes in samples
requiring as little as 500 pg of unfixed RNA or 5 ng of FFPE RNA. The
assay yields greater than 5 logs of dynamic range for up to 300 genes in a
single tube assay.
oIon AmpliSeq™ DNA Custom Mouse Panel uses a single pool of primers with up
to 6,144 amplicons and requires just 10 ng of genomic DNA to target up to
5 Mb of mouse genomic regions.
Ion Torrent™ services continue to improve in performance and simplicity of
data analysis, with advances in three key areas:
oTorrent Browser Plug-in Store enables anyone to create and share plug-ins
that provide additional data analysis functionality within Torrent Suite™
Software. In less than a year, over 35 plug-ins have been contributed to
the Ion Community and over 6,000 have been downloaded.
oTorrent Suite™ Software v3.4 and the new Torrent Variant Caller offer
integrated signal processing, base calling, mapping and variant detection,
and a new compressed file format, all delivered through a web browser and
preconfigured on a Torrent Server. This software is available for download
oIon Reporter™ Software v1.4 is a streamlined bioinformatics solution that
enables scientists to identify and interpret human genetic variants from
either the Ion PGM™ or Ion Proton™ sequencers. The software brings rich
genomic annotation, easy-to-use filters and reproducible analysis to
molecular biologists. Researchers can try Ion Reporter™ Software for free
through May 31, 2013.
All products referenced are for research use only and not for use in
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a
global biotechnology company with customers in more than 160 countries using
its innovative solutions to solve some of today's most difficult scientific
challenges. Quality and innovation are accessible to every lab with its
reliable and easy-to-use solutions spanning the biological spectrum, with more
than 50,000 products for agricultural biotechnology, translational research,
molecular medicine and diagnostics, stem cell-based therapies, forensics, food
safety and animal health. Its systems, reagents and consumables represent some
of the most cited brands in scientific research including: Ion Torrent™,
Applied Biosystems®, Invitrogen™, Gibco®, Ambion®, Molecular Probes® and
Novex®. Life Technologies employs approximately 10,400 people and upholds its
ongoing commitment to innovation with more than 4,000 patents and exclusive
licenses. LIFE had sales of $3.8 billion in 2012. Visit us at our website:
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made by Life Technologies with the Securities and Exchange
Commission. Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact
SOURCE Life Technologies Corporation
Press spacebar to pause and continue. Press esc to stop.